I-MAB advances repositioned RA drug in early trial to treat COVID-19 cytokine storm

China-based I-MAB Biopharma, fueled by a recent $104 million initial public offering, has joined the effort to speed medicines to market that can treat cytokine release syndrome. The company said last week that it saw positive results from a small clinical study of its experimental drug TJM2 and is progressing to part two of the study.